Literature DB >> 30674530

Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors.

Pauline J Beckmann1, Jon D Larson1, Alex T Larsson1, Jason P Ostergaard1, Sandra Wagner1, Eric P Rahrmann1,2, Ghaidan A Shamsan3, George M Otto1,4, Rory L Williams1,5, Jun Wang6, Catherine Lee6, Barbara R Tschida1, Paramita Das1, Adrian M Dubuc7, Branden S Moriarity1, Daniel Picard8,9, Xiaochong Wu10, Fausto J Rodriguez11, Quincy Rosemarie1,12, Ryan D Krebs1, Amy M Molan1,13, Addison M Demer1, Michelle M Frees1, Anthony E Rizzardi14, Stephen C Schmechel14,15, Charles G Eberhart16, Robert B Jenkins17, Robert J Wechsler-Reya6, David J Odde3, Annie Huang18, Michael D Taylor10, Aaron L Sarver1, David A Largaespada19.   

Abstract

Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble human Sonic hedgehog and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 activation. This represents the first genetically induced mouse model of CNS-PNET and a rare model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET. SIGNIFICANCE: A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30674530      PMCID: PMC6397665          DOI: 10.1158/0008-5472.CAN-18-1261

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

Review 2.  Ambra1 in cancer: implications for clinical oncology.

Authors:  Yan-Qiu Qin; Si-Yu Liu; Mei-Ling Lv; Wei-Liang Sun
Journal:  Apoptosis       Date:  2022-08-22       Impact factor: 5.561

3.  The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors.

Authors:  Jasmin Bartl; Marco Zanini; Flavia Bernardi; Antoine Forget; Lena Blümel; Julie Talbot; Daniel Picard; Nan Qin; Gabriele Cancila; Qingsong Gao; Soumav Nath; Idriss Mahoungou Koumba; Marietta Wolter; François Kuonen; Maike Langini; Thomas Beez; Christopher Munoz; David Pauck; Viktoria Marquardt; Hua Yu; Judith Souphron; Mascha Korsch; Christina Mölders; Daniel Berger; Sarah Göbbels; Frauke-Dorothee Meyer; Björn Scheffler; Barak Rotblat; Sven Diederichs; Vijay Ramaswamy; Hiromishi Suzuki; Anthony Oro; Kai Stühler; Anja Stefanski; Ute Fischer; Gabriel Leprivier; Dieter Willbold; Gerhard Steger; Alexander Buell; Marcel Kool; Peter Lichter; Stefan M Pfister; Paul A Northcott; Michael D Taylor; Arndt Borkhardt; Guido Reifenberger; Olivier Ayrault; Marc Remke
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

Review 4.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

5.  Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells.

Authors:  Aaron L Sarver; Chencheng Xie; Megan J Riddle; Colleen L Forster; Xiaohong Wang; Huarui Lu; Wyatt Wagner; Jakub Tolar; Timothy C Hallstrom
Journal:  Lab Invest       Date:  2021-03-03       Impact factor: 5.662

Review 6.  Modeling pediatric medulloblastoma.

Authors:  Martine F Roussel; Jennifer L Stripay
Journal:  Brain Pathol       Date:  2019-12-17       Impact factor: 7.611

Review 7.  Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities.

Authors:  Pauline J Beckmann; David A Largaespada
Journal:  Int J Mol Sci       Date:  2020-02-10       Impact factor: 5.923

8.  Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.

Authors:  Lynn M Heltemes-Harris; Gregory K Hubbard; Rebecca S LaRue; Sarah A Munro; Rendong Yang; Christine M Henzler; Timothy K Starr; Aaron L Sarver; Steven M Kornblau; Michael A Farrar
Journal:  Oncogene       Date:  2021-09-17       Impact factor: 9.867

9.  [MiR- 4719 inhibits migration and invasion of human breast cancer cells via targeting ARHGAP36].

Authors:  Q Li; Y Qiu; T Jin; M Liu; Y Hou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-06-20

10.  Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.

Authors:  Deyin Xing; Chien-Fu Hung; Ssu-Hsueh Tseng; Sung-Taek Park; Brandon Lam; Ya-Chea Tsai; Max A Cheng; Emily Farmer
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.